Naloxon Hci B. Braun (Naloxone Hydrochloride)

Naloxone works by competitively binding to μ‑opioid receptors in the central nervous system without activating them. This displaces opioid molecules from the receptors, blocking further opioid signaling and quickly restoring normal respiratory drive and alertness in patients who have received an opioid overdose.

The specific dose of Naloxon Hci B. Braun is determined by the prescribing clinician based on the patient’s condition, the opioid involved, and the route of administration. Healthcare professionals follow established clinical guidelines to select an appropriate dose for each emergency situation.

Safety data for naloxone in pregnancy and lactation are limited. Because naloxone does not cross the placenta in significant amounts and is not excreted in breast milk in clinically relevant concentrations, it is generally considered low risk, but clinicians should weigh potential benefits against any unknown risks.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After verification of trade or institutional credentials, the sales team will provide pricing, availability, shipping details (including any cold‑chain requirements), and import documentation.

Naloxone is the most widely used opioid antagonist due to its rapid onset, short duration of action, and well‑established safety profile. Compared with alternatives such as nalmefene, naloxone has a quicker peak effect, making it preferred for emergency reversal of opioid overdose.

Naloxon Hci B. Braun should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from direct sunlight, moisture, and extreme temperature fluctuations to maintain potency and sterility.

The product is supplied as a sterile injectable solution for intramuscular (IM) or intravenous (IV) injection. Administration is performed by trained healthcare professionals, who inject the appropriate dose directly into a muscle or vein, followed by immediate monitoring of the patient’s respiratory status.

Serious risks include severe hypertension, cardiac arrhythmias, pulmonary edema, seizures, anaphylaxis, and precipitated acute opioid withdrawal, especially in patients with physical dependence. Prompt medical observation is essential to manage these potential complications.

Naloxone is contraindicated in patients with known hypersensitivity to naloxone or any component of the formulation. Caution is advised for individuals with severe cardiovascular disease, as rapid reversal of opioid effects can cause abrupt hemodynamic changes.